By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

The majority of men in the UK will not be offered prostate cancer screening following a final recommendation from a committee ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...